Top Sanofi vaccine execs, Bristol Myers vet chart new path for IGM's antibodies in infectious diseases, autoimmunity
When IGM Biosciences made its public debut two years ago, the S-1 pitch was heavily centered on how its engineered IgM antibodies could make potent cancer treatments. But it also buried a reference, deep inside a section about the platform’s potential, about how these antibodies may be applied in a variety of conditions — citing autoimmune diseases and infectious diseases as examples.
The biotech is now creating new business units to expand its work in those exact areas. And it’s recruited a trio of experts from Big Pharma to lead them.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.